3E Bioventures
Cenova leads $40m Series B for China's Eluminex
China-based healthcare investor Cenova Capital has led a USD 40m Series B round for Eluminex Biosciences, which is developing drugs and regenerative tissue used to treat eye disease and other vision-threatening medical conditions.
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
Chinese investors lead round for US influenza specialist
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.
SDIC, Sherpa lead $74m round for China's EpimAb
Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has raised a $74 million Series B round led by SDIC Fund Management and healthcare specialist Sherpa Healthcare Partners.
China's SenseTime closes $410m Series B round
Sense Time, a Chinese artificial intelligence (AI) and deep learning technology start-up has closed a $410 million Series B round of funding across two tranches, led by CDH Investments and Sailing Capital, respectively.
Corporate VC in China healthcare: Formula for success
Despite the rapid growth of the Chinese pharmaceutical industry, corporate venture capital so far has not built a large presence. Industry participants say this shows the market, though booming, is still immature